Calton & Associates’s NanoViricides NNVC Stock Holding History

Calton & Associates’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-145	Closed	-$2K	–	957
2017 Q4	$2K	Buy	+145	New	+$2.96K	﹤0.01%	1399

Other funds holding NNVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

PTB

Pioneer Trust Bank Salem, Oregon $441M AUM 21.13% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

Calton & Associates's NNVC Position: Q1 2018 in Review

Calton & Associates sold out of NanoViricides (NNVC) in Q1 2018, closing a stake of 145 shares — an estimated $2K sold.

Calton & Associates first reported a position in NNVC in Q4 2017 and held it in 1 quarter. The position peaked at $2K in Q4 2017. 38 funds tracked by Wall St. Rank hold NNVC as of Q1 2018.

Calton & Associates reported no remaining NanoViricides position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 145 NanoViricides shares in Q1 2018, an estimated $2K.
Calton & Associates first reported a position in NanoViricides in Q4 2017 and held it in 1 quarter.
Calton & Associates's NanoViricides position peaked at $2K in Q4 2017.
38 funds tracked by Wall St. Rank held NanoViricides as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.